Impact of Nirsevimab Implementation on the Mid-Term Burden of Bronchiolitis in the Outpatient Setting: Results from the Prospective OURSYN Study.

IF 3.3 4区医学 Q3 INFECTIOUS DISEASES

Journal of the Pediatric Infectious Diseases Society Pub Date : 2026-06-12 DOI:10.1093/jpids/piag035

Lea Lenglart, Corinne Levy, Fabienne Cahn-Sellem, Morched Zouari, Frederic Hassid, Stéphane Béchet, Maeva Boulhol, Rolf Kramer, Alexis Rybak, Naim Ouldali, Robert Cohen

{"title":"Impact of Nirsevimab Implementation on the Mid-Term Burden of Bronchiolitis in the Outpatient Setting: Results from the Prospective OURSYN Study.","authors":"Lea Lenglart, Corinne Levy, Fabienne Cahn-Sellem, Morched Zouari, Frederic Hassid, Stéphane Béchet, Maeva Boulhol, Rolf Kramer, Alexis Rybak, Naim Ouldali, Robert Cohen","doi":"10.1093/jpids/piag035","DOIUrl":null,"url":null,"abstract":"Context: Nirsevimab was implemented in Europe and the United States in September 2023. While its effectiveness in preventing respiratory syncytial virus (RSV)-bronchiolitis has been demonstrated by real-life studies, its impact on mid-term child health, quality of life, and parental absenteeism remains unstudied.Methods: Infants under 1-year with a first bronchiolitis episode were recruited through the OURSYN study involving 37 primary care pediatricians in France between 2021 and 2025 (pre-nirsevimab period: 02/2021-03/2023 and nirsevimab period: 09/2023-03/2025). RSV status was determined by antigenic nasopharyngeal testing. At day 15, parents reported symptoms, quality of life (PedsQL Infant), and work absenteeism. Their associations with (i) RSV status, (ii) period of inclusion, and (iii) nirsevimab immunization status among RSV-positive cases were assessed using multivariable logistic regression adjusted for confounders.Results: Among 1870 bronchiolitis cases included, 637 (34.0%) occurred during the nirsevimab period and 812 (43.4%) were RSV-related. Over the study period, at day 15, RSV-cases had more feeding difficulties (aOR = 1.41 [1.06-1.88]), longer daycare absence (4.7 vs. 3.2 days), and more parental absenteeism (aOR = 1.61 [0.99-2.62]) compared to RSV-negative. The proportion of RSV-cases decreased during the nirsevimab period compared with the pre-nirsevimab period (47.1% vs. 35.7% P < .001). Bronchiolitis cases recruited during this period had shorter daycare absences (3.2 vs. 4.3 days). Among RSV-cases, immunized infants had lower risk of persistent fever (aOR = 0.14 [0.01-0.79]).Conclusion: This large prospective study provides the first evidence that the mid-term burden of RSV-bronchiolitis in infants may be reduced following the implementation of nirsevimab, with potential benefits for infant health, quality of life and parental absenteeism.","PeriodicalId":17374,"journal":{"name":"Journal of the Pediatric Infectious Diseases Society","volume":" ","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2026-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Pediatric Infectious Diseases Society","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/jpids/piag035","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Context: Nirsevimab was implemented in Europe and the United States in September 2023. While its effectiveness in preventing respiratory syncytial virus (RSV)-bronchiolitis has been demonstrated by real-life studies, its impact on mid-term child health, quality of life, and parental absenteeism remains unstudied.

Methods: Infants under 1-year with a first bronchiolitis episode were recruited through the OURSYN study involving 37 primary care pediatricians in France between 2021 and 2025 (pre-nirsevimab period: 02/2021-03/2023 and nirsevimab period: 09/2023-03/2025). RSV status was determined by antigenic nasopharyngeal testing. At day 15, parents reported symptoms, quality of life (PedsQL Infant), and work absenteeism. Their associations with (i) RSV status, (ii) period of inclusion, and (iii) nirsevimab immunization status among RSV-positive cases were assessed using multivariable logistic regression adjusted for confounders.

Results: Among 1870 bronchiolitis cases included, 637 (34.0%) occurred during the nirsevimab period and 812 (43.4%) were RSV-related. Over the study period, at day 15, RSV-cases had more feeding difficulties (aOR = 1.41 [1.06-1.88]), longer daycare absence (4.7 vs. 3.2 days), and more parental absenteeism (aOR = 1.61 [0.99-2.62]) compared to RSV-negative. The proportion of RSV-cases decreased during the nirsevimab period compared with the pre-nirsevimab period (47.1% vs. 35.7% P < .001). Bronchiolitis cases recruited during this period had shorter daycare absences (3.2 vs. 4.3 days). Among RSV-cases, immunized infants had lower risk of persistent fever (aOR = 0.14 [0.01-0.79]).

Conclusion: This large prospective study provides the first evidence that the mid-term burden of RSV-bronchiolitis in infants may be reduced following the implementation of nirsevimab, with potential benefits for infant health, quality of life and parental absenteeism.

查看原文本刊更多论文

尼西维单抗对门诊细支气管炎中期负担的影响：来自前瞻性OURSYN研究的结果

背景：Nirsevimab于2023年9月在欧洲和美国实施。虽然它在预防rsv -细支气管炎方面的有效性已被现实生活中的研究证明，但它对中期儿童健康、生活质量和父母缺勤的影响仍未得到研究。方法：通过OURSYN研究招募首次毛细支气管炎发作的1岁以下婴儿，该研究涉及法国的37名初级保健儿科医生，研究时间为2021年至2025年（尼塞米单抗前期：2021年2月至2023年3月，尼塞米单抗期：9月至2023年3月）。采用鼻咽抗原检测检测RSV状态。在第15天，父母报告症状、生活质量（PedsQL婴儿）和旷工情况。它们与RSV阳性病例(i) RSV状态、（ii）纳入时间和（iii） nirsevimab免疫状态的相关性通过校正混杂因素的多变量logistic回归进行评估。结果：纳入的1870例细支气管炎病例中，637例（34.0%）发生在尼塞维单抗治疗期间，812例（43.4%）与rsv相关。在研究期间，在第15天，与rsv阴性病例相比，rsv病例有更多的喂养困难（aOR = 1.41[1.06-1.88]），更长时间的日托缺勤（4.7 vs 3.2天），更多的父母缺勤（aOR = 1.61[0.99-2.62]）。结论：这项大型前瞻性研究提供了第一个证据，证明在使用尼西维单抗后，婴儿rsv -细支气管炎的中期负担可能会减少，对婴儿健康、生活质量和父母缺缺率有潜在的好处。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of the Pediatric Infectious Diseases Society Medicine-Pediatrics, Perinatology and Child Health

CiteScore

6.70

自引率

0.00%

发文量

179

期刊介绍： The Journal of the Pediatric Infectious Diseases Society (JPIDS), the official journal of the Pediatric Infectious Diseases Society, is dedicated to perinatal, childhood, and adolescent infectious diseases. The journal is a high-quality source of original research articles, clinical trial reports, guidelines, and topical reviews, with particular attention to the interests and needs of the global pediatric infectious diseases communities.